NanoVibronix Inc Net Assets
NanoVibronix Inc net assets. Based on the latest financial reports, NanoVibronix Inc (NAOV) has net assets worth $42.46 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($54.38 Million) and total liabilities ($11.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NAOV shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $42.46 Million |
| % of Total Assets | 78.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | -73.81% |
| 10-Year Change | N/A |
| Growth Volatility | 106.29 |
Net Assets of NanoVibronix Inc (2011–2024)
Net assets of NanoVibronix Inc from 2011 to 2024. This chart illustrates how NanoVibronix Inc's net assets have evolved over time, based on quarterly financial data. See NanoVibronix Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for NanoVibronix Inc (2011–2024)
The table below shows the annual net assets of NanoVibronix Inc from 2011 to 2024. For live market cap and overall valuation, see NanoVibronix Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $627.00K | -84.28% |
| 2023-12-31 | $3.99 Million | +23.35% |
| 2022-12-31 | $3.23 Million | -48.79% |
| 2021-12-31 | $6.31 Million | +163.70% |
| 2020-12-31 | $2.39 Million | +77.60% |
| 2019-12-31 | $1.35 Million | +191.14% |
| 2018-12-31 | $463.00K | -87.26% |
| 2017-12-31 | $3.63 Million | +245.42% |
| 2016-12-31 | $-2.50 Million | -1095.69% |
| 2015-12-31 | $-209.00K | +96.28% |
| 2014-12-31 | $-5.62 Million | -70.34% |
| 2013-12-31 | $-3.30 Million | -79.97% |
| 2012-12-31 | $-1.83 Million | -213.16% |
| 2011-12-31 | $-585.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NanoVibronix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5886200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
NanoVibronix Inc Net Assets Breakdown (December 2024)
NanoVibronix Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.48% |
| Other Comprehensive Income | $-80.00K | -12.76% |
| Other Components | $70.50 Million | 11244.82% |
| Total Equity | $627.00K | 100.00% |
NanoVibronix Inc Competitors by Market Cap
The table below lists competitors of NanoVibronix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Innity Corporation Bhd
KLSE:0147
|
$4.37 Million |
|
Sawang Export Public Company Limited
BK:SAWANG
|
$4.38 Million |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
$4.38 Million |
|
Newton Golf Company
NASDAQ:NWTG
|
$4.38 Million |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
$4.37 Million |
|
CPPGroup Plc
F:4CV1
|
$4.37 Million |
|
AHT Syngas Technology NV
F:3SQ1
|
$4.37 Million |
|
Neola Medical AB
ST:NEOLA
|
$4.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NanoVibronix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,988,000 to 627,000, a change of -3,361,000 (-84.3%).
- Net loss of 3,705,000 reduced equity.
- Other comprehensive income decreased equity by 13,000.
- Other factors increased equity by 357,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.71 Million | -590.91% |
| Other Comprehensive Income | $-13.00K | -2.07% |
| Other Changes | $357.00K | +56.94% |
| Total Change | $- | -84.28% |
Book Value vs Market Value Analysis
This analysis compares NanoVibronix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-44.80 | $4.10 | x |
| 2012-12-31 | $-140.31 | $4.10 | x |
| 2013-12-31 | $-252.52 | $4.10 | x |
| 2014-12-31 | $-430.13 | $4.10 | x |
| 2015-12-31 | $-11.82 | $4.10 | x |
| 2016-12-31 | $-10.92 | $4.10 | x |
| 2017-12-31 | $146.41 | $4.10 | x |
| 2018-12-31 | $14.36 | $4.10 | x |
| 2019-12-31 | $38.85 | $4.10 | x |
| 2020-12-31 | $46.49 | $4.10 | x |
| 2021-12-31 | $50.18 | $4.10 | x |
| 2022-12-31 | $22.77 | $4.10 | x |
| 2023-12-31 | $22.79 | $4.10 | x |
| 2024-12-31 | $2.32 | $4.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NanoVibronix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -590.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -144.84%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 5.79x
- Recent ROE (-590.91%) is below the historical average (-194.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -769.15% | 0.09x | 0.00x | $-664.50K |
| 2012 | 0.00% | -768.07% | 0.48x | 0.00x | $-1.09 Million |
| 2013 | 0.00% | -942.65% | 0.31x | 0.00x | $-1.66 Million |
| 2014 | 0.00% | -1303.94% | 0.28x | 0.00x | $-2.09 Million |
| 2015 | 0.00% | -1961.90% | 0.07x | 0.00x | $-2.86 Million |
| 2016 | 0.00% | -1236.24% | 0.46x | 0.00x | $-2.58 Million |
| 2017 | -136.63% | -2077.41% | 0.05x | 1.34x | $-5.33 Million |
| 2018 | -897.19% | -1306.29% | 0.20x | 3.41x | $-4.20 Million |
| 2019 | -429.82% | -1093.21% | 0.26x | 1.51x | $-5.93 Million |
| 2020 | -180.70% | -694.38% | 0.08x | 3.44x | $-4.57 Million |
| 2021 | -226.23% | -842.60% | 0.20x | 1.37x | $-14.91 Million |
| 2022 | -168.51% | -724.47% | 0.13x | 1.82x | $-5.77 Million |
| 2023 | -93.05% | -162.55% | 0.34x | 1.67x | $-4.11 Million |
| 2024 | -590.91% | -144.84% | 0.70x | 5.79x | $-3.77 Million |
Industry Comparison
This section compares NanoVibronix Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NanoVibronix Inc (NAOV) | $42.46 Million | 0.00% | 0.28x | $4.37 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more